Elan Prialt pricing
Executive Summary
Annualized price for Elan's non-opioid pain agent Prialt (ziconotide) for typical patient weighing 70 kg is $18,250, assuming dosing every six weeks. Elan describes Prialt rollout as a "quiet launch" focusing on 50 pain centers. FDA approved the product Dec. 28 and Elan launched the week of Jan. 24 (1"The Pink Sheet" Jan. 3, 2005, p. 4)...
You may also be interested in...
Elan Prialt Clears FDA; Half Of Projected Market Does Not Have Delivery Pump
Elan estimates that more than half of the 120,000 potential users of its non-opioid analgesic Prialt do not already possess an internal drug delivery pump expected to be used in ziconotide administrations
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.